Cancer stem cells (CSCs) are responsible for tumor progression,metastases,resistance to therapy,and tumor recurrence. Therefore,the identification of molecules involved in CSC self-renewal is a necessary step toward more effective therapies. To this aim,through the transcription profiling of the murine ErbB2(+) tumor cell line TUBO vs. derived CSC-enriched mammospheres,Toll-like receptor 2 (TLR2) was identified as 2-fold overexpressed in CSCs,as confirmed by qPCR and cytofluorimetric analysis. TLR2 signaling inhibition impaired in vitro mammosphere generation in murine TUBO (60%) and 4T1 (30%) and human MDA-MB-231 (50%),HCC1806 (60%),and MCF7 (50%) cells. In CSC,TLR2 was activated by endogenous high-mobility-group box 1 (HMGB1),inducing I$$B$$ phosphorylation,IL-6 and TGF$$ secretion,and,consequently,STAT3 and Smad3 activation. In vivo TLR2 inhibition blocked TUBO tumor takes in 9/14 mice and induced a 2-fold reduction in lung metastases development by decreasing cell proliferation and vascularization and increasing apoptosis. Collectively,these results demonstrate that murine and human mammary CSCs express TLR2 and its ligand HMGB1; this autocrine loop plays a pivotal role in CSC self-renewal,tumorigenesis,and metastatic ability. These findings,while providing evidence against the controversial use of TLR2 agonists in antitumor therapy,lay out new paths toward the design of anticancer treatments.
View Publication